WallStreetZenWallStreetZen

NASDAQ: ILMN
Illumina Inc Stock Forecast, Predictions & Price Target

Analyst price target for ILMN

Based on 12 analysts offering 12 month price targets for Illumina Inc.
Min Forecast
$175.00-16.15%
Avg Forecast
$247.33+18.51%
Max Forecast
$300.00+43.75%

Should I buy or sell ILMN stock?

Based on 12 analysts offering ratings for Illumina Inc.
Buy
Strong Buy
3 analysts 25%
Buy
3 analysts 25%
Hold
4 analysts 33.33%
Sell
0 analysts 0%
Strong Sell
2 analysts 16.67%

Be the first to know when Wall Street analysts revise their ILMN stock forecasts and price targets.

ILMN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Canaccord Genuity
Bottom 1%
1
Strong BuyMaintains$300.00+43.75%2023-01-17
ScotiaBank
Top 23%
78
HoldInitiates Coverage On$216.00+3.50%2023-01-05
Citigroup
Top 5%
96
Strong SellDowngrades$180.00-13.75%2022-12-12
RBC Capital
Top 40%
61
BuyInitiates Coverage On$282.00+35.12%2022-12-07
Piper Sandler
Top 25%
76
Strong BuyMaintains$300.00+43.75%2022-11-14
Morgan Stanley
Bottom 5%
5
HoldMaintains$225.00+7.81%2022-11-07
Credit Suisse
Top 7%
94
HoldMaintains$225.00+7.81%2022-11-04
SVB Leerink
Bottom 2%
2
BuyUpgrades$270.00+29.37%2022-10-04
Barclays
Bottom 2%
2
Strong SellMaintains$175.00-16.15%2022-09-30
Evercore ISI Group
Bottom 5%
5
BuyUpgrades$250.00+19.79%2022-09-28

1 of 2

Forecast return on equity

Is ILMN forecast to generate an efficient return?
Company
13.58%
Industry
-20.91%
Market
47.78%
ILMN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ILMN forecast to generate an efficient return on assets?
Company
8.12%
Industry
12.04%
ILMN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ILMN earnings per share forecast

What is ILMN's earnings per share in the next 2 years based on estimates from 8 analysts?
Avg 1 year Forecast
$4.38
Avg 2 year Forecast
$5.81

ILMN revenue forecast

What is ILMN's revenue in the next 2 years based on estimates from 6 analysts?
Avg 1 year Forecast
$5.6B+19.47%
Avg 2 year Forecast
$6.6B+40.15%
ILMN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ILMN revenue growth forecast

How is ILMN forecast to perform vs Diagnostics & Research companies and vs the US market?
Company
19.47%
Industry
5.61%
Market
72.18%
ILMN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ILMN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ILMN vs Diagnostic & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
ILMN$208.70$247.33+18.51%Buy
MTD$1,555.98$1,425.60-8.38%Buy
IDXX$485.53$479.44-1.25%Strong Buy
DXCM$106.73$178.92+67.64%Strong Buy
IQV$232.31$251.47+8.25%Strong Buy

Illumina Stock Forecast FAQ

Is Illumina Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 12 Wall Street analysts covering (NASDAQ: ILMN) stock is to Buy ILMN stock.

Out of 12 analysts, 3 (25%) are recommending ILMN as a Strong Buy, 3 (25%) are recommending ILMN as a Buy, 4 (33.33%) are recommending ILMN as a Hold, 0 (0%) are recommending ILMN as a Sell, and 2 (16.67%) are recommending ILMN as a Strong Sell.

If you're new to stock investing, here's how to buy Illumina stock.

What is ILMN's earnings growth forecast for 2023-2024?

(NASDAQ: ILMN) Illumina's forecast annual earnings growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 33.33%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 85.2%.

Illumina's earnings in 2023 is -$4,153,000,000.On average, 8 Wall Street analysts forecast ILMN's earnings for 2023 to be $688,974,000, with the lowest ILMN earnings forecast at $591,448,000, and the highest ILMN earnings forecast at $895,037,000.

In 2024, ILMN is forecast to generate $913,913,000 in earnings, with the lowest earnings forecast at $778,635,000 and the highest earnings forecast at $1,132,560,000.

What is ILMN's revenue growth forecast for 2023-2024?

(NASDAQ: ILMN) Illumina's forecast annual revenue growth rate of 19.47% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 72.18%.

Illumina's revenue in 2023 is $4,699,000,000.On average, 6 Wall Street analysts forecast ILMN's revenue for 2023 to be $883,062,694,800, with the lowest ILMN revenue forecast at $836,505,670,000, and the highest ILMN revenue forecast at $956,352,540,000.

In 2024, ILMN is forecast to generate $1,035,958,609,400 in revenue, with the lowest revenue forecast at $963,147,900,000 and the highest revenue forecast at $1,145,408,264,000.

What is ILMN's forecast return on assets (ROA) for 2023-2024?

(NASDAQ: ILMN) forecast ROA is 8.12%, which is lower than the forecast US Diagnostics & Research industry average of 12.04%.

What is ILMN's Price Target?

According to 12 Wall Street analysts that have issued a 1 year ILMN price target, the average ILMN price target is $247.33, with the highest ILMN stock price forecast at $300.00 and the lowest ILMN stock price forecast at $175.00.

On average, Wall Street analysts predict that Illumina's share price could reach $247.33 by Jan 17, 2024. The average Illumina stock price prediction forecasts a potential upside of 18.51% from the current ILMN share price of $208.70.

What is ILMN's Earnings Per Share (EPS) forecast for 2023-2024?

(NASDAQ: ILMN) Illumina's current Earnings Per Share (EPS) is -$26.43. On average, analysts forecast that ILMN's EPS will be $4.38 for 2023, with the lowest EPS forecast at $3.76, and the highest EPS forecast at $5.69. In 2024, ILMN's EPS is forecast to hit $5.81 (min: $4.95, max: $7.20).

What is ILMN's forecast return on equity (ROE) for 2023-2024?

(NASDAQ: ILMN) forecast ROE is 13.58%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.